Biomarker Study with FDG-PET/CT Analysis in Induction Chemo-radiation Therapy Followed by Surgery with Perioperative Immunotherapy for Resectable Stage Discreate N2 IIIA-B Non-small Cell Lung Cancer (SQUAT-TR2 Study) ( WJOG12119LTR2)

Biomarker Study with FDG-PET/CT Analysis in Induction Chemo-radiation Therapy Followed by Surgery with Perioperative Immunotherapy for Resectable Stage Discreate N2 IIIA-B Non-small Cell Lung Cancer (SQUAT-TR2 Study) ( WJOG12119LTR2) - WJOG12119LTR2:SQUAT-TR2 study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060836

Enrollment

Registered

2026-03-05

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were enrolled in WJOG12119L and, at the time of enrollment in the present study, had not withdrawn their informed consent for that trial.

Exclusion criteria

Exclusion criteria: Patients deemed inappropriate for inclusion by the attending physician.

Design outcomes

Primary

Measure	Time frame
Association between pathological response (pCR/MPR) and FDG-PET/CT parameters	—

Countries

Japan

Contacts

Public ContactNaoki Ishizuka

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results